Clinical trials
for patients
Learn about available clinical trials
-
June 10, 2026Pamplona/MadridIn recruitmentEarly phase
CTL-002-004 Randomized, blinded, placebo-controlled phase 2 clinical trial investigating the efficacy and safety of visugromab and nivolumab, with or without docetaxel, compared with docetaxel alone.
The aim of this clinical trial is to determine the efficacy of a new drug called “visugromab” (also known as “CT-L002”) and its safety when administered in combination with nivolumab and docetaxel. CT-L002 and nivolumab help the immune system fight cancer. Docetaxel interferes with the growth of cancer cells, leading to their destruction. CT-L002 has not yet been approved for any patients outside research studies. -
June 10, 2026Pamplona/MadridIn recruitmentEarly phase
M25-279 Phase II clinical study to evaluate the safety and efficacy of Telisotuzumab Adizutecan in the treatment of subjects with locally advanced or metastatic solid tumors with MET amplification.
The aim of this study is to evaluate the efficacy, safety and tolerability of Temab-A as monotherapy in patients with locally advanced or metastatic solid tumors with MET gene amplification. -
June 10, 2026PamplonaIn recruitment
22931 Clinical trial conducted in humans to evaluate the safety of BAY 3713372 and how it works in participants with solid tumors with MTAP gene deletion
The aim of this trial is: -To see whether the new treatment BAY 3713372 has any effect, good or bad. -To find the best dose of BAY 3713372 to give to participants. -To understand what happens to BAY 3713372 once it is in the body. -To understand how the drug affects your body. -To understand how the treatment affects your disease. -To learn how different types and amounts of food affect the way the body absorbs the trial drug. -
June 8, 2026Pamplona/MadridIn recruitmentEarly phase
CTL-002-005 A clinical trial investigating the efficacy and safety of visugromab in combination with nivolumab and lenvatinib compared with a double-blind placebo and lenvatinib in participants with unresectable or metastatic hepatocellular carcinoma and ....
The purpose of this trial is to determine how well a new drug currently in development called visugromab (also known as CTL-002) works and whether it is safe when used in combination with nivolumab and lenvatinib. -
June 3, 2026PamplonaIn recruitmentEarly phase
TV56286-NDG-20041 Ensayo clínico para describir la seguridad y la eficacia de TEV-56286 (Emrusolmin) en participantes con atrofia multisistémica
The objective of this study is to evaluate the long-term tolerability and safety of the investigational drug TEV-56286 in people with AMS. -
June 2, 2026PamplonaIn recruitment
LB208-1-002 Multicenter, open-label, phase I/II study of LB-208, a selective antagonist of the 5-hydroxytryptamine serotonin receptor 1B (HTR1B), in adults with relapsed or refractory (r/r) acute myeloid leukemia (AML) and high-risk (HR) relapsed or refractory (r/r) myelodysplastic syndrome (MDS).
The objective of this trial, which involves research, is to examine the safety and efficacy of an investigational drug called LB-208. Investigational means that the investigational drug to be tested in this clinical trial has not been authorized by national drug regulatory agencies, such as the Spanish Agency of Medicines and Medical Devices. -
June 2, 2026Pamplona/MadridIn recruitment
STK-012-101 Phase I/II study of STK-012 as monotherapy and in combination therapy in solid tumors.
The primary objective of this study is to determine whether STK-012 administered together with standard-of-care treatment is more effective in treating cancer than standard-of-care treatment alone in patients with lung cancer. STK-012 is a new investigational drug being studied by the sponsor. -
June 2, 2026MadridIn recruitmentEarly phase
2001-0001 Clinical trial to investigate how people with advanced cancer (solid tumors) tolerate different doses of BI 3820768.
Phase I study to determine the safety and tolerability of BI 3820768 in patients with advanced, relapsed, or treatment-refractory germ cell tumors, endometrial cancer, or ovarian cancer. -
May 27, 2026Pamplona/MadridIn recruitment
GCT1184-03 Phase III clinical trial of rinatabart sesutecan (Rina-S) compared with investigator’s choice of treatment in patients with endometrial cancer following platinum-based chemotherapy and PD(L)-1 therapy
The primary objective is to compare the clinical efficacy of Rina-S with the investigator’s choice (IC) of treatment in patients with recurrent or progressive endometrial cancer (EC) following prior treatment. -
May 25, 2026MadridIn recruitment
MK-2870-021 Clinical trial of sacituzumab timurotecan (sac-TMT, MK-2870) as maintenance therapy in participants with advanced ovarian cancer
The primary objective is to compare sac-TMT maintenance therapy with or without bevacizumab against standard of care (SoC) in terms of PFS as defined by RECIST 1.1, as assessed by the BICR.